Study of remibrutinib for moderate to severe hidradenitis suppurativa
Part of Infections, Skin clinical trials.
This study tests a new oral medication, remibrutinib, in adults with moderate to severe hidradenitis suppurativa (HS), a skin condition causing painful lumps and tunnels. The goal is to see how the drug affects the skin tissue and to gather information for future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have had hidradenitis suppurativa for at least 6 months.
- You have at least 5 painful bumps or boils (abscesses or inflammatory nodules) in at least 2 different areas (like both armpits).
- You have at least one long-lasting lesion with a draining tunnel.
- You have not taken remibrutinib or other BTK inhibitors before.
- You have not taken investigational JAK inhibitors before.
- You do not have active infections (like tuberculosis, HIV) or liver disease.
- You have no significant bleeding risk or clotting disorder.
- If you are a woman who can become pregnant, you must use highly effective birth control during the study and for 7 days after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
This trial tests a new drug called Brivekimig for people with moderate to severe hidradenitis suppurativa (HS) who have not gotten enough relief from oral antibiotics. The goal is to see if it can reduce abscesses and inflamed bumps.
This trial tests a new medication, SAR445399, for people with moderate to severe hidradenitis suppurativa (HS) who haven't improved with oral antibiotics. It aims to see if the drug safely reduces skin bumps and abscesses.
This trial tests a new medicine called HB0043 for people with moderate to severe hidradenitis suppurativa (a skin condition causing painful lumps). It aims to see if the drug is safe and helps reduce symptoms.
This study tests a cream called ruxolitinib for people with hidradenitis suppurativa (HS). The goal is to see how much of the cream is absorbed when it's applied to a large area of the body.
This study tests a new drug called LAD328 for hidradenitis suppurativa (HS), a chronic skin condition with painful lumps and abscesses. The trial is looking for adults with moderate-to-severe HS who haven't responded well to antibiotics to see if this new treatment can help reduce symptoms.
Hear when a new Hidradenitis Suppurativa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.